New inhaler could reduce rescue treatments in hospitalized COPD patients
NCT ID NCT05292053
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a once-daily inhaler called Trelegy Ellipta in 80 adults hospitalized for a COPD flare-up. The goal was to see if it reduces the need for extra rescue breathing treatments and shortens hospital stays. Participants took the inhaler daily along with short-term steroids and were followed for 30 days after leaving the hospital.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol)
What this could lead to
If successful, this could show that a once-daily inhaler helps hospitalized COPD patients need fewer rescue treatments and have shorter hospital stays.
What could go wrong
This is a small, single-center study with only 80 participants, so results may not apply to all COPD patients. It is also open-label, meaning both patients and doctors knew the treatment, which can bias results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Scott & White Health Research Institute
Dallas, Texas, 75246, United States